EC
AQST icon

EntryPoint Capital’s Aquestive Therapeutics AQST Stock Holding History

EntryPoint Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,745
Closed -$186K – 744
2025
Q4 		$186K Hold
28,745
– – 0.07% 566
2025
Q3 		$161K Sell
28,745
-120,411
-81% -$521K 0.06% 580
2025
Q2 		$494K Sell
149,156
-43,600
-23% -$125K 0.25% 102
2025
Q1 		$559K Buy
192,756
+56,959
+42% +$172K 0.26% 73
2024
Q4 		$483K Buy
135,797
+112,210
+476% +$517K 0.2% 118
2024
Q3 		$117K Sell
23,587
-38,614
-62% -$150K 0.07% 545
2024
Q2 		$162K Buy
+62,201
New +$208K 0.08% 519

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

EntryPoint Capital's AQST Position: Q1 2026 in Review

EntryPoint Capital sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 28,745 shares — an estimated $186K sold.

EntryPoint Capital first reported a position in AQST in Q2 2024 and held it in 7 quarters. The position peaked at $559K in Q1 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • EntryPoint Capital reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 28,745 Aquestive Therapeutics shares in Q1 2026, an estimated $186K.
  • EntryPoint Capital first reported a position in Aquestive Therapeutics in Q2 2024 and held it in 7 quarters.
  • EntryPoint Capital's Aquestive Therapeutics position peaked at $559K in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.